Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

The requested reference [1371907c3dad7213f92f76df6e36688b0daa3060] no longer exists in our database. It has been replaced by the current reference: [0d117b07f45d0c28677eb2414cbfd1c261eb5d96]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
Epistemonikos ID: bc7e59c6bf6fae67b8cf81d465c454778600a55c
First added on: Jun 10, 2023